Endpoints with 24 weeks | HETROM-2.5, n = 168 | HETROM-5, n = 171 | Hetrombopag, n = 339 |
---|---|---|---|
Proportion of patients who responded at ≥ 75% of their platelet count assessments | |||
 n (%; 95% CI)‡ | 67 (39.9; 32.4–47.7) | 85 (49.7; 42.0–57.4) | 152 (44.8; 39.5–50.3) |
Maximum continuous duration of response | |||
 n# | 138 | 149 | 287 |
 Median (range), days | 64.0 (8.0–165.0) | 64.0 (6.0–168.0) | 64.0 (6.0–168.0) |
Total duration of response | |||
 n# | 138 | 149 | 287 |
 Median (range), days | 101.0 (8.0–165.0) | 104.0 (6.0–168.0) | 103.0 (6.0–168.0) |